Isoquercetin for ovarian cancer patients
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests if a plant-based supplement called isoquercetin can help people with ovarian cancer when given alongside their first chemotherapy. It aims to see if it improves treatment results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian cancer (a type called epithelial, serous, or clear cell).
- You are about to start or are in your first or second cycle of chemotherapy.
- You are at least 18 years old.
- Your doctor expects you to live more than 6 months.
- You are generally active and able to do daily activities (performance status score of 0 or 1).
- You have no history of blood clots, bleeding problems, or use of blood thinners in the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This trial tests a combination treatment for advanced ovarian cancer that hasn't been treated before. It combines chemotherapy, a personalized vaccine made from your own immune cells, and a drug called pembrolizumab to help your immune system fight the cancer.
This early-phase study tests whether adding aspirin to standard neoadjuvant chemotherapy can change immune (anti-tumor) features inside ovarian, fallopian tube, or peritoneal tumors. It may help doctors better understand which patients respond and how aspirin could make treatment work better.
This study tests a new pill called INCB123667 for people with a type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow their growth.
This study tests whether adding a statin (a common cholesterol-lowering drug) to standard chemotherapy can improve outcomes for people with ovarian cancer. It's for women who are about to receive chemotherapy as part of their treatment plan.
This early-phase trial tests a lab-made immune cell treatment designed to recognize ovarian cancer and attack it. It may help people with high-risk ovarian cancer who still need effective options.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.